Inaccurate pretreatment staging can impact survival in early stage esophageal adenocarcinoma

2020 ◽  
Author(s):  
Anthony J. Scholer ◽  
Abhineet Uppal ◽  
Shu‐Ching Chang ◽  
Debopriya Ghosh ◽  
Mary Garland‐ Kledzik ◽  
...  
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Early Stage ◽  
Pretreatment Staging

Defining low-risk lesions in early-stage esophageal adenocarcinoma

2020 ◽  
Author(s):  
Smita Sihag ◽  
Sergio De La Torre ◽  
Meier Hsu ◽  
Tamar Nobel ◽  
Kay See Tan ◽  
...  
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Early Stage ◽  
Low Risk

352 Treatment Allocation in Early Stage Esophageal Adenocarcinoma: the National Incidence Rates and Predictors of Lymph Node Involvement

2014 ◽  
Vol 79 (5) ◽  
pp. AB133 ◽  
Author(s):  
Anthony M. Gamboa ◽  
Sungjin Kim ◽  
Kevin E. Woods ◽  
Seth D. Force ◽  
Shishir K. Maithel ◽  
...  
Keyword(s):  
Lymph Node ◽  
Esophageal Adenocarcinoma ◽  
Early Stage ◽  
Lymph Node Involvement ◽  
Incidence Rates ◽  
Treatment Allocation ◽  
Node Involvement

scholarly journals Treatment of Early-Stage Esophageal Adenocarcinoma

2013 ◽  
Vol 11 (6) ◽  
pp. 640-644
Author(s):  
Ariel Polish ◽  
Mary F. Mulcahy
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Early Stage

scholarly journals Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Emily M. Christman ◽  
Parthasarathy Chandrakesan ◽  
Nathaniel Weygant ◽  
John T. Maple ◽  
William M. Tierney ◽  
...  
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Early Stage ◽  
Serum Levels

Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4015-4015 ◽  
Author(s):  
Richard C. Turkington ◽  
Laura A. Hill ◽  
Damian McManus ◽  
Stephen McQuaid ◽  
Ken Arthur ◽  
...  
Keyword(s):  
Dna Damage ◽  
Esophageal Adenocarcinoma ◽  
Dna Damage Response ◽  
Early Stage ◽  
Damage Response

Complement component C9 as a new biomarker for esophageal adenocarcinoma.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 19-19 ◽  
Author(s):  
Virendra Joshi ◽  
Alok Shah ◽  
Ian Brown ◽  
Clay Winterford ◽  
Michelle Hill
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Early Stage ◽  
Multiple Reaction Monitoring ◽  
Diagnostic Value ◽  
Complement Component ◽  
Endoscopic Surveillance ◽  
Disease Stage ◽  
Receiver Operating Curve ◽  
Diagnostic Tools ◽  
Serum Glycoprotein

19 Background: Esophageal adenocarcinoma (EAC) continues an upward trend. Mortality rate and treatment costs for EAC are very high overall and significantly increase with disease stage. Diagnosis at early stage (T1) compared to advanced stage (T3) improves 5 year survival from 20% to 80-90%. Endoscopic surveillance has been ineffective in reducing EAC. Therefore the need for better diagnostic tools for early detection.Previously we reported validation of a list of serum glycoprotein biomarker candidates for EAC in an Australian cohort (Shah et al. 2015 Mol Cell Proteomics. 14:3023-39.). Here we further evaluate the serum and tissue expression of top candidate C9 in an independent cohort from the USA. Methods: Serum samples (n=38) and FFPE tissue sections (n=34) were collected from participants with IRB approved protocol, from the Ochsner Clinic undergoing endoscopic surveillance for Barrett’s and esophageal cancer. Serum glycoprotein candidates were measured using lectin magnetic bead array-coupled multiple reaction monitoring assay (Shah et al. 2015 Mol Cell Proteomics. 14:3023-39.). Immunohistochemistry was optimised for complement component C9 antibody. Initial evaluation of 2 different antibodies gave similar results, thereafter, a polyclonal antibody from Sigma Aldrich was used. Staining was assessed by a gastrointestinal pathologist. Results: Specific glycosylated forms of 3 candidate serum biomarkers were confirmed to be significantly different between EAC and benign groups (p<0.05, Kruskal-Wallis). The diagnostic value for the 3 individual markers, complement component C9, gelsolin and alpha-1-antichymotrypsin (Serpin A3) was 0.71 to 0.82 area under the receiver operating curve (AUROC). A multivariate panel consisting of 8 glycoprotein biomarkers achieved AUROC of 0.96, indicative of high diagnostic value. Immunohistochemistry of tissues detected high levels of C9 in BE and EAC compared to normal squamous epithelium. Infiltrated lymphocytes showed variable staining. Conclusions: We propose a novel candidate biomarker complement component C9 which could add to current endoscopic surveillance strategy for early detection of adenocarcinoma.

Sign in / Sign up

Export Citation Format

Share Document